NUVB•benzinga•
Nuvation Bio shares are trading higher after the company announced the FDA accepted the New Drug Application for taletrectinib for the treatment of advanced ROS1+ NSCLC.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga